New ways to image and target tumour hypoxia and its molecular responses.
Tumour hypoxia and its molecular responses have been shown to be associated with poor prognosis. Detection of hypoxia, preferably in a non-invasive manner, could therefore predict treatment outcome and serve as a tool to individualize treatment. This review gives an overview of recent literature on hypoxia imaging markers currently used in clinical trials. Furthermore, recent progress made in targeting hypoxia (hypoxia-activated prodrugs) or hypoxia response (carbonic anhydrase IX inhibitors) is summarized. Last, window-of-opportunity trials implementing non-invasive imaging are proposed as an important tool to prove anti-tumour efficacy of experimental drugs early during drug development.
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands. Electronic address: ludwig.dubois@maastrichtuniversity.nl.
Ludwig J
LJ
Dubois
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Raymon
R
Niemans
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Simon J A
SJ
van Kuijk
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Kranthi M
KM
Panth
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands; Institut des Biomolecules Max Mousseron (IBMM), UMR 5247 CNRS, Université Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), France.
Nanda-Kumar
NK
Parvathaneni
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Sarah G J A
SG
Peeters
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Catharina M L
CM
Zegers
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Nicolle H
NH
Rekers
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Marike W
MW
van Gisbergen
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Rianne
R
Biemans
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Natasja G
NG
Lieuwes
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Linda
L
Spiegelberg
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Ala
A
Yaromina
Institut des Biomolecules Max Mousseron (IBMM), UMR 5247 CNRS, Université Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), France.
Jean-Yves
JY
Winum
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Marc
M
Vooijs
Dept. of Radiation Oncology (MAASTRO Lab), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands.
Philippe
P
Lambin
D006801:Humans; D000860:Hypoxia / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D049268:Positron-Emission Tomography
Carbonic anhydrase IX; Hypoxia; Imaging; Therapy; Window-of-opportunity trial